Beneficial results and improved progression-free survival in cases of recurrent glioblastoma were presented recently for bevacizumab (Avastin), a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) ligand, inhibiting further activation of its receptors [175]. The gene discussed is VEGFA; the disease is glioblastoma.